Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases
Authors
Keywords
-
Journal
DIGESTIVE DISEASES AND SCIENCES
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-04
DOI
10.1007/s10620-021-07073-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
- (2020) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Patient preferences for maintenance therapy in Crohn’s disease: A discrete-choice experiment
- (2020) Glen S. Hazlewood et al. PLoS One
- Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
- (2020) Matthew Bohm et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications
- (2020) Laura E Targownik et al. Journal of Crohns & Colitis
- Long-term safety of vedolizumab for inflammatory bowel disease
- (2020) Edward V. Loftus et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review
- (2020) Marie Muller et al. Journal of Crohns & Colitis
- Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis
- (2019) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study
- (2019) Tomer Adar et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases
- (2019) Ariela Holmer et al. Expert Review of Clinical Immunology
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
- (2019) Timothy Card et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease
- (2018) S. Singh et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn’s Disease With up to 6 Years of Follow-Up in the Pyramid Registry
- (2018) Geert D’Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Upfront Combination Therapy, Compared with Monotherapy, for Patients Not Previously Treated with a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study
- (2018) Laura E. Targownik et al. Clinical Gastroenterology and Hepatology
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
- (2017) Magali Lemaitre et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inflammatory Bowel Disease Patients’ Willingness to Accept Medication Risk to Avoid Future Disease Relapse
- (2015) Meenakshi Bewtra et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
- (2014) K. P. Garnock-Jones BIODRUGS
- Optum Labs: Building A Novel Node In The Learning Health Care System
- (2014) Paul J. Wallace et al. HEALTH AFFAIRS
- Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease
- (2014) Nynne Nyboe Andersen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases
- (2012) Kevin Haynes et al. ARTHRITIS AND RHEUMATISM
- Rates of malignancy associated with juvenile idiopathic arthritis and its treatment
- (2012) Timothy Beukelman et al. ARTHRITIS AND RHEUMATISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search